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Introduction
Breast cancer is one of the most common cancers with an increasing mortality worldwide, while ovarian cancer is less frequent than breast cancer but is often fatal. 1 Clinically, treatment of advanced breast cancer is often futile, and therefore, early diagnosis is critical to the therapy of breast cancer. In most cases, breast cancer occurs during the post-menopausal period, in which ovarian estrogen is no longer produced. 2 It was reported that a number of novel genetic mutations were found in 228 he and shen inherited breast and ovarian cancer patients. 3 For example, mutations in BRCA1 and BRCA2 genes were often detected in the hereditary breast and ovarian cancer patients. 4 Of hereditary breast and ovarian cancers, the familial hereditary variations accounted for only 10%. 5 A previous study in American populations indicated that many molecular mutations were observed in both sporadic breast cancer and sporadic ovarian cancer. 1 Six genetic techniques, including genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing, and reverse-phase protein arrays, were used to detect gene mutations in this study. The data, concerning genetic variations of breast cancer and ovarian cancer, were calculated using statistical methods. Obviously, similar molecule mutations were found in both sporadic breast cancer and sporadic ovarian cancer. In addition, some other studies, focusing on rare genes such as PALB2, ATM, CHEK2, BRIP1, RAD51C, and PPMID, were performed, and these studies have also found few common genetic mutations. 6 These risk modifiers could be applied to the early treatments of cancers, which is important for intensive screening and prophylactic surgery of cancer patients. The elucidation of risk allele is also helpful for clarifying the pathogenic mechanisms of cancers.
The gene, encoding methylenetetrahydrofolate reductase (MTHFR), is located at 1p36.3 and is highly polymorphic, in which the C677T polymorphic variant is most commonly studied and it can lead to Ala222Val. 7 The MTHFR C677T polymorphism could reduce the production of MTHFR and affect enzyme activity. 8 MTHFR is a crucial enzyme which has an important role in the regulation of methionine and homocysteine concentrations in folate metabolism. 9 Folate is a necessity in intracellular metabolic processes such as DNA and RNA synthesis, DNA repair, and DNA methylation. 10 Folate could regulate the transfer of one carbon unit in various biochemical reactions, which is complicated in various pathological processes such as breast cancer, ovarian cancer, colorectal cancer, gastric cancer, and lung cancer. 11, 12 Although many studies are conducted to investigate the association between MTHFR C677T polymorphism and breast and ovarian cancer, there is no conclusive evidence that MTHFR C677T is a common risk factor for breast cancer and ovarian cancer due to the influences of many factors such as ethnicity, source of control, and sample size.
Therefore, this study has performed this meta-analysis based on published eligible case-control studies to evaluate the role of MTHFR C677T polymorphism in breast cancer and/or ovarian cancer risk.
Materials and methods

Publication search
PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), WanFang, and Database of Chinese Scientific and Technical Periodicals (VIP) were searched to identify the articles that investigate the association of MTHFR C677T polymorphism with breast and ovarian cancer risk. The retrieval was performed using the keywords: "breast neoplasms," "breast cancer," "breast carcinoma," "ovarian carcinoma," "ovarian neoplasms," "ovarian cancer," "MTHFR," "Methylenetetrahydrofolate Reductase (NADPH2)," "C677T," "rs1801133," and the latest search was updated until June 2016. In addition, articles published only in English and Chinese were identified, while the fulltext of the retrieved articles was scrutinized to confirm that these data were required for this study.
inclusion and exclusion criteria
Studies were included if they met the following inclusion criteria: 1) case-control studies, 2) investigating the association of MTHFR C677T polymorphism with breast and ovarian cancer risk, 3) genotype data of cases and controls were complete, and 4) genotype distribution of control must comply with the Hardy-Weinberg equilibrium (HWE). The exclusion criteria were as follows: 1) duplicated studies, 2) no detailed information of genotype data, and 3) meta-analysis and reviews.
Data extraction
Two authors assessed the quality of the included studies independently and extracted the following information: the name of first author, year of publication, country of origin, ethnicity, sample size, and genotype data. In case of conflicting information, divergence was resolved through discussion with the team. The population was divided into the Asians and Caucasians.
Quality score assessment
The quality of the included studies was assessed with the Newcastle-Ottawa scale (NOS) (http://www.ohri.ca/ programs/clinical_epidemiology/oxford.asp) table. Two authors calculated the score of each study, respectively. The maximum score was 9, and a score $7 denoted that the study was of high quality.
statistical analysis
HWE of the included studies was assessed with χ 2 test. The odds ratios (ORs) and 95% confidence intervals (CIs) were
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MTHFR C677T polymorphism and breast and ovarian cancer risk calculated to evaluate the association between MTHFR C677T and breast and ovarian cancer risk. 13 Allele model, co-dominant model, dominant model, recessive model, and homozygous model were utilized to assess the association of the MTHFR C677T polymorphism with the risk of breast cancer and/or ovarian cancer. Moreover, a subgroup analysis based on ethnicity and source of control were conducted to reduce the heterogeneity. The chi-square-based Q test (P,0.05, the significant level of statistical heterogeneity) and I 2 index (I 2 $50%, the significant level of statistical heterogeneity) were used to evaluate the inconsistencies among studies, and the two values were shown on the forest plots. 14, 15 The fixed effect model, deriving from the Mantel-Haenszel method, was applied when heterogeneity did not exist, and the random effect model, depending on the DerSimonian and Laird method, was carried out in case of significant heterogeneity. 16, 17 Egger's test and Begg's test were conducted to examine the publication bias. 18 Sensitivity analysis was performed by removing each study and was applied to observe stabilization of the results. All statistical analyses were conducted using Stata (version 12.0; StataCorp LP, College Station, TX, USA) software. In addition, the P-value is two sided, and P,0.05 was considered statistically significant.
Results
literature selection
A total of 137 articles with 6 reviews and 22 meta-analyses were retrieved in initial search from PubMed, Embase, Web of Science, CNKI, WanFang, and VIP databases. About 28 articles were excluded as they were not case-control studies; 70 articles were included after analyzing the titles and abstracts; and 8 articles were excluded after reading the full-text. HWE was carried out to analyze the genetic equilibrium of the included studies, and 12 studies were excluded (P,0.05). [19] [20] [21] [22] [23] [24] [25] [26] Finally, 50 publications, involving 19,260 cases and 26,364 controls, were selected in this metaanalysis. The information of first author, ethnicity, nationality, cancer type, genotyping method, source of control, and genotype frequency was extracted (Table 1, Figure 1 ).
Quantitative analysis
In the overall and subgroup analysis, five genetic models were applied to evaluate the association of MHTFR C677T polymorphism with the risk of breast cancer and/or ovarian cancer. The results indicated that there was a significant correlation between MTHFR C677T polymorphism and breast cancer risk: allele model C vs T, OR =1. 19 (Table 3 ). In addition, forest plots have been drawn to observe the weight of each included study and estimate the association of MTHFR C677T polymorphism with the relative risk of breast cancer and/or ovarian cancer using the homozygous genetic model (CC vs TT). In the meantime, the stratified analyses based on ethnicity, cancer type, and control type were conducted to eliminate the heterogeneity among studies (Figures 2 and 3 ).
sensitivity analysis and publication bias
Sensitivity analysis indicated that the results were stable, and the summary ORs were not materially altered by excluding individual data set at each time. Moreover, no significant publication bias was shown according to Begg's test and Egger's test (Figures 4-6 ).
Discussion
In previous studies, strong evidences show that genetic variations, involving DNA metabolism, existed in breast cancer and/or ovarian cancer. 27, 28 Because of the central roles of these genes in cell metabolism, the changes in the functions of these genes may increase the risk of cancers. As is well known, MTHFR C677T polymorphism could alter MTHFR enzyme activity, which affected the general balance in the process of DNA repair, DNA methylation, and DNA synthesis. 29 Therefore, MTHFR might have a potential effect 
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MTHFR C677T polymorphism and breast and ovarian cancer risk on the origin and progress of breast cancer and ovarian cancer. 30 Several studies have been conducted to evaluate the contribution of MTHFR C677T polymorphism to breast and ovarian cancer, but the sample size, ethnicity, and the source of control were limited. 31, 32 In the study of Lu et al, the results suggested that MTHFR C677T polymorphism might be significantly associated with the risk and prognosis of breast cancer in Chinese population. 33 Although the age has been corrected and the genotype data of control comply with the law of HWE in this study, the conclusion was still indeterminable because of small sample size and the influence of other environmental factors. The same results were also observed in other studies. [34] [35] [36] In addition, there was a common problem in the studied Chinese populations, that is, the population of control often came from the hospital. This might reduce the persuasion of research results. Hence, in the meta-analysis, the subgroup analysis based on the source of control was conducted to increase the power of statistics and achieve a more accurate result. On the other hand, significant association between MTHFR C677T and breast cancer risk was also detected in Caucasians. 37, 38 However, contrasting results were described in Asians and Caucasians for breast cancer risk. [39] [40] [41] [42] [43] In the studies for ovarian cancer, Gao et al found that the MTHFR C677T polymorphism was significantly associated with the susceptibility and the survival of ovarian cancer. 31, 45, 46 Nevertheless, other results indicated that no association of MTHFR C677T polymorphism with ovarian cancer risk existed. 47, 48 The different results from these studies showed that the correlation between MTHFR C677T polymorphism and breast cancer and/or ovarian cancer risk were still inconclusive. Hence, the pooled analysis was carried out to analyze the correlation of MTHFR C677T polymorphism with breast cancer and/or ovarian cancer risk.
In the overall analysis, the results suggested that the MTHFR C677T polymorphism might significantly increase the breast cancer risk but not ovarian cancer risk. The CC genotype carriers had a higher breast cancer risk than showed that the hospital-based case-control studies mainly contributed to the heterogeneity among ovarian cancer research studies. Based on the included studies for breast cancer, it could be mentioned that the main cause of heterogeneity might be ethnicity. In the stratified meta-analysis based on ethnicity for breast cancer, compared with C allele, a significantly increased breast cancer risk was significantly associated with T allele in Asians (C vs T, P,0.05, OR =1. 12 Several factors such as selection criteria of cases, age distribution, sample size, family history, ethnicity, source of control, and lifestyle might lead to the heterogeneity among studies. There was no significant publication bias based on Begg's test and Egger's test. In addition, no significant changing of the results was found in sensitivity analysis, which demonstrated the results were stable in the meta-analysis. And the studies that were not consistent with the HWE in the meta-analysis were excluded in order to improve the accuracy of the results.
According to the results, it was clear that the MTHFR C677T variant could increase the breast cancer and/or ovarian cancer risk in Asians. These results provided obvious evidence that metabolism genes could increase the risk of breast and ovarian cancer. Most notably, because of some genetic differences in Asians and Caucasians, the MTHFR C677T polymorphism might have a different effect on breast cancer and/or ovarian cancer in the two populations. But given the different role of gene variations in cell differentiation and proliferation, the function experiment and clinic trial were still needed to confirm the conclusions of this meta-analysis. 49 Furthermore, environmental factors might have an important influence in breast cancer and/or ovarian cancer risk. Hence, it was expected that studies including environmental factors were carried out. In summary, this meta-analysis demonstrated that the MTHFR C677T mutation might increase the risk of both breast cancer and ovarian cancer, especially in Asians. It provided a new insight into the molecular origin of breast cancer and ovarian cancer. Considering the limitations of the study, large well-designed studies including different ethnic populations should be conducted to further assess the association of the MTHFR C677T polymorphisms with increased susceptibility to breast cancer and/or ovarian cancer.
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